Table 3 Efficacy Evaluation of Imatinib in CML Patients by Disease Stage
From: Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006
CP | AP | BC | P value | ||
|---|---|---|---|---|---|
Primary n = 84(%) | IFN Failure n = 70(%) | n = 25(%) | n = 38(%) | ||
CHR | 80(95.2) | 62(88.6) | 18(72.0) | 18(47.4) | <0.0001 |
MCyR | 71(84.5) | 45(64.3) | 8(32.0) | 7(18.4) | <0.0001 |
CCyR | 62(73.8) | 37(52.9) | 6(24.0) | 4(10.5) | <0.0001 |